NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INGN stock has increased by 28.9% and is now trading at $52.34. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) released its quarterly earnings data on Tuesday, February, 25th. The medical technology company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.11 by $0.17. The medical technology company earned $78.92 million during the quarter, compared to analyst estimates of $90.11 million. Inogen had a return on equity of 7.07% and a net margin of 5.79%. The firm's revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.44 earnings per share. View Inogen's earnings history.

Inogen issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $403.47 million.

6 analysts have issued 1-year price objectives for Inogen's stock. Their forecasts range from $45.00 to $90.00. On average, they expect Inogen's stock price to reach $62.00 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View analysts' price targets for Inogen.

News headlines about INGN stock have trended very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inogen earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutInogen.

Inogen saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 2,380,000 shares, a decline of 6.3% from the February 13th total of 2,540,000 shares. Based on an average daily volume of 352,500 shares, the days-to-cover ratio is currently 6.8 days. Approximately 13.1% of the shares of the stock are short sold. View Inogen's Current Options Chain.

Some companies that are related to Inogen include MSA Safety (MSA), Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), Lakeland Industries (LAKE), RTI Surgical (RTIX), Sientra (SIEN), Allied Healthcare Products (AHPI), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Bionik Laboratories (BNKL) and NanoVibronix (NAOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Square (SQ).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $52.34.

Inogen has a market capitalization of $1.15 billion and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe. View additional information about Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]